# Heart Matters

Since cardiovascular disease is one of the leading causes of death in the U.S., cardiology physicians are continuously working to better understand this common disease and to help patients improve their heart health. And here to assist cardiology physicians in this mission is Heart Matters, a series dedicated to covering essential strategies and research efforts focusing on all types of heart problems, including coronary artery diseases, heart attacks, high cholesterol, high blood pressure, and…

Page: <https://rssamplifier.com/heart-matters>  
Feed: <https://rssamplifier.com/heart-matters.md>

---

## [From Goals to Action: Multisociety Guidance on Lipid Management](https://reachmd.com/programs/heart-matters/lipid-goals-management-multisociety-guideline/54148/)

_2026-08-19_

Guest: Ann Marie Navar, MD, PhD With LDL cholesterol goals reinstated in the 2026 American College of Cardiology and American Heart Association Guideline on the Management of Dyslipidemia, we now have a clearer framework for intensifying lipid-lowering therapy. Dr. Ann Marie Navar explains how to select nonstatin therapies based on the degree of LDL lowering needed, patient preferences, and the…

[Listen](https://reachmd.com/programs/heart-matters/lipid-goals-management-multisociety-guideline/54148/podcast/104318.mp3?partner=itunes&category_id=42)

## [Managing Dyslipidemia: 2026 ACC/AHA Guideline Updates](https://reachmd.com/programs/heart-matters/manage-dyslipidemia-acc-aha-guideline-updates-2026/54150/)

_2026-08-19_

Guest: Roger Blumenthal, MD What do the 2026 American College of Cardiology (ACC) and American Heart Association (AHA) dyslipidemia guideline updates mean for patient care? Join Dr. Roger Blumenthal, Chair of the Guideline Writing Committee, as he reviews key recommendations that can help us personalize cardiovascular risk reduction and improve long-term prevention. Dr. Blumenthal is the Kenneth…

[Listen](https://reachmd.com/programs/heart-matters/manage-dyslipidemia-acc-aha-guideline-updates-2026/54150/podcast/104469.mp3?partner=itunes&category_id=42)

## [How PCSK9 Inhibition Lowers LDL Cholesterol](https://reachmd.com/programs/heart-matters/pcsk9-inhibition-ldl-cholesterol/54151/)

_2026-08-19_

Guest: Ann Marie Navar, MD, PhD How does PCSK9 inhibition lower LDL cholesterol? Find out as Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, explains the biology behind this therapeutic approach.

[Listen](https://reachmd.com/programs/heart-matters/pcsk9-inhibition-ldl-cholesterol/54151/podcast/104321.mp3?partner=itunes&category_id=42)

## [Enlicitide for LDL-C Management: Insights from CORALreef Lipids](https://reachmd.com/programs/heart-matters/enlicitide-ldl-c-management-coralreef-lipids/54152/)

_2026-08-19_

Guest: Ann Marie Navar, MD, PhD The CORALreef Lipids trial helped establish the clinical evidence supporting the FDA approval of enlicitide for LDL-C management. Join Dr. Ann Marie Navar, Associate Professor of Cardiology at the University of Texas Southwestern Medical Center, for a discussion of the trial's efficacy, safety, and durability. She also explores key considerations for integrating…

[Listen](https://reachmd.com/programs/heart-matters/enlicitide-ldl-c-management-coralreef-lipids/54152/podcast/104327.mp3?partner=itunes&category_id=42)

## [Risk Prediction with the PREVENT-ASCVD Equations](https://reachmd.com/programs/heart-matters/risk-prediction-prevent-ascvd-equations/54153/)

_2026-08-19_

Guest: Roger Blumenthal, MD As the drivers of cardiovascular disease have shifted over time, so have the tools used to estimate risk. Dr. Roger Blumenthal explains why the PREVENT-ASCVD equations represent an important advance over traditional models and what that means for more accurate, individualized preventive care. Dr. Blumenthal is the Kenneth Jay Pollin Professor of Cardiology and Director…

[Listen](https://reachmd.com/programs/heart-matters/risk-prediction-prevent-ascvd-equations/54153/podcast/104472.mp3?partner=itunes&category_id=42)

## [The Patient You Might Be Missing: Severe Hypertriglyceridemia in Clinical Practice](https://reachmd.com/programs/medical-industry-feature/the-patient-you-might-be-missing-severe-hypertriglyceridemia-in-clinical-practice/54272/)

_2026-08-14_

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erin D. Michos, MD, MHS Severe hypertriglyceridemia (sHTG) affects more than 3 million people, but it often flies under the clinical radar. 1-3 When triglycerides are at or above a 500 mg/dL threshold, it’s no longer just an isolated lab value—it’s a level of hypertriglyceridemia where the clinical implications change, and where a more careful…

[Listen](https://reachmd.com/programs/medical-industry-feature/the-patient-you-might-be-missing-severe-hypertriglyceridemia-in-clinical-practice/54272/podcast/96903.mp3?partner=itunes&category_id=42)

## [Evaluating ASCVD Risk with the CPR Framework](https://reachmd.com/programs/heart-matters/evaluate-ascvd-risk-cpr-framework/67137/)

_2026-08-10_

Guest: Roger Blumenthal, MD The 2026 American College of Cardiology (ACC) and American Heart Association (AHA) Guideline on the Management of Dyslipidemia highlights the CPR framework—Calculate, Personalize, Reclassify, and Reassess—to support individualized atherosclerotic cardiovascular disease (ASCVD) risk assessment and treatment decisions. Dr. Roger Blumenthal, Chair of the Guideline Writing…

[Listen](https://reachmd.com/programs/heart-matters/evaluate-ascvd-risk-cpr-framework/67137/podcast/104475.mp3?partner=itunes&category_id=42)

## [Looking Ahead in ATTR-CM Care: Improving Diagnosis, Outcomes, and Equity](https://reachmd.com/programs/heart-matters/attr-cm-equity-outcomes/49076/)

_2026-07-02_

Guest: Frederick Ruberg, MD What will the future of transthyretin amyloid cardiomyopathy (ATTR-CM) care look like? Dr. Frederick Ruberg joins us to share his perspective on the advances that may shape the next phase of patient care, from screening and therapeutic strategies to expanded genetic testing aimed at identifying patients earlier. He's the Chief of Cardiovascular Medicine at Boston…

[Listen](https://reachmd.com/programs/heart-matters/attr-cm-equity-outcomes/49076/podcast/97703.mp3?partner=itunes&category_id=42)

## [Hypertension in Women: Cardiovascular Risk Across the Lifespan](https://reachmd.com/programs/heart-matters/hypertension-women-cv-risk-lifespan/56370/)

_2026-07-01_

Host: Shelina Ramnarine, PhD Guest: Payal Kohli, MD, FACC In women, hypertension follows a distinct biological and clinical course that evolves across reproductive and menopausal transitions, but its long-term implications remain underrecognized and undertreated. In this expert-led discussion, Dr. Shelina Ramnarine and Dr. Payal Kohli examine key considerations in managing hypertension in women…

[Listen](https://reachmd.com/programs/heart-matters/hypertension-women-cv-risk-lifespan/56370/podcast/93152.mp3?partner=itunes&category_id=42)

## [Get started with Turso (Sponsored)](https://crawlproof.com/a/46YJSv8u2DuY)

_2026-07-01 · **Sponsored**_

Create your Turso account to access the app.

## [Early Recognition of ATTR-CM: Key Signs and Diagnostic Strategies](https://reachmd.com/programs/heart-matters/early-recognition-attr-cm-signs-diagnosis/49067/)

_2026-06-25_

Guest: Valmiki Maharaj, MD With increasing recognition and more accessible diagnostic tools, ATTR-CM can no longer be overlooked in patients with atypical heart failure presentations. Dr. Valmiki Maharaj shades insights on connecting clinical clues, confirming diagnosis efficiently, and acting earlier to meaningfully impact long-term outcomes. He's the Director of the Heart Failure Clinic, the…

[Listen](https://reachmd.com/programs/heart-matters/early-recognition-attr-cm-signs-diagnosis/49067/podcast/91607.mp3?partner=itunes&category_id=42)

